David Dobbs writes features and essays for publications including The New York Times, National Geographic, Slate, Wired.com, The New York Times Magazine, and other publications. Several of his stories have been chosen for leading science anthologies; most recently, his much-discussed feature for ...
The Atlantic has done so many things well in its move online that I was among the many readers and journalists flabbergasted when it teamed with the Church of Scientology to repeat a mistake that had already been made more than two years ago, in almost exactly the same form, when Seed sold a blog spot to Pepsigate.
Did the genomic revolution arrive last week, or was that just the snowstorm? The answer depends on whom you listened to and what they thought of a study published on March 17 that showed a gene-based drug called Repatha reduced cardiovascular risk by 15%.
The United States Food and Drug Administration is not known for its prose. So the warning letter that it sent to 23andMe, the direct-to-consumer genetic-testing company, on November 22nd, was a surprise in more ways than one. "It reads like the letter of a jilted lover," Misha Angrist, a former genetic counsellor who writes about personal genomics and teaches at Duke University, said.